Cannabinoid CB1 Discrimination: Effects of Endocannabinoids and Catabolic Enzyme Inhibitors.

Abstract

An improved understanding of the endocannabinoid system has provided new avenues of drug discovery and development toward the management of pain and other behavioral maladies. Exogenous cannabinoid type 1 (CB1) receptor agonists such as Δ9-tetrahydrocannabinol are increasingly used for their medicinal actions; however, their utility is constrained by… (More)
DOI: 10.1124/jpet.117.244392

Topics

1 Figure or Table

Cite this paper

@article{Leonard2017CannabinoidCD, title={Cannabinoid CB1 Discrimination: Effects of Endocannabinoids and Catabolic Enzyme Inhibitors.}, author={Michael Z. Leonard and Shakiru O. Alapafuja and Lipin Ji and Vidyanand G. Shukla and Yingpeng Liu and Spyros P. Nikas and Alexandros Makriyannis and J. Peder Bergman and Brian D. Kangas}, journal={The Journal of pharmacology and experimental therapeutics}, year={2017}, volume={363 3}, pages={314-323} }